Kelly Scaggs Campen
Examiner (ID: 2758, Phone: (571)272-6740 , Office: P/3691 )
Most Active Art Unit | 3691 |
Art Unit(s) | 3624, 2165, 2164, 3312, 3738, 3691 |
Total Applications | 1052 |
Issued Applications | 501 |
Pending Applications | 228 |
Abandoned Applications | 322 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 16571019
[patent_doc_number] => 20210010025
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-14
[patent_title] => TREATMENT OF OCULAR DISEASES WITH HUMAN POST-TRANSLATIONALLY MODIFIED VEGF-TRAP
[patent_app_type] => utility
[patent_app_number] => 16/810422
[patent_app_country] => US
[patent_app_date] => 2020-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27771
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 86
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16810422
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/810422 | TREATMENT OF OCULAR DISEASES WITH HUMAN POST-TRANSLATIONALLY MODIFIED VEGF-TRAP | Mar 4, 2020 | Pending |
Array
(
[id] => 17453251
[patent_doc_number] => 11268097
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-03-08
[patent_title] => Inhibition of SEMA3A in the prevention and treatment of ocular hyperpermeability
[patent_app_type] => utility
[patent_app_number] => 16/808611
[patent_app_country] => US
[patent_app_date] => 2020-03-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 8
[patent_no_of_words] => 14546
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16808611
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/808611 | Inhibition of SEMA3A in the prevention and treatment of ocular hyperpermeability | Mar 3, 2020 | Issued |
Array
(
[id] => 16468218
[patent_doc_number] => 20200369755
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-26
[patent_title] => ANTIBODIES RECOGNIZING TAU
[patent_app_type] => utility
[patent_app_number] => 16/808209
[patent_app_country] => US
[patent_app_date] => 2020-03-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 53247
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -46
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16808209
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/808209 | Antibodies recognizing tau | Mar 2, 2020 | Issued |
Array
(
[id] => 16283760
[patent_doc_number] => 20200277362
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-03
[patent_title] => Humanized Antibodies That Recognize Alpha-Synuclein
[patent_app_type] => utility
[patent_app_number] => 16/795479
[patent_app_country] => US
[patent_app_date] => 2020-02-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16459
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16795479
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/795479 | Humanized antibodies that recognize alpha-synuclein | Feb 18, 2020 | Issued |
Array
(
[id] => 16093563
[patent_doc_number] => 20200200768
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-25
[patent_title] => NOVEL BIOMARKERS FOR COGNITIVE IMPAIRMENT AND METHODS FOR DETECTING COGNITIVE IMPAIRMENT USING SUCH BIOMARKERS
[patent_app_type] => utility
[patent_app_number] => 16/791984
[patent_app_country] => US
[patent_app_date] => 2020-02-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10699
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16791984
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/791984 | Biomarkers for cognitive impairment and methods for detecting cognitive impairment using such biomarkers | Feb 13, 2020 | Issued |
Array
(
[id] => 16361024
[patent_doc_number] => 20200317775
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-08
[patent_title] => SP35 Antibodies And Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 16/789738
[patent_app_country] => US
[patent_app_date] => 2020-02-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 59488
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16789738
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/789738 | SP35 Antibodies And Uses Thereof | Feb 12, 2020 | Abandoned |
Array
(
[id] => 16650004
[patent_doc_number] => 10927167
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-02-23
[patent_title] => Anti-complement factor C1Q antibodies and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/784020
[patent_app_country] => US
[patent_app_date] => 2020-02-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 10
[patent_no_of_words] => 35321
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 91
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16784020
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/784020 | Anti-complement factor C1Q antibodies and uses thereof | Feb 5, 2020 | Issued |
Array
(
[id] => 16525272
[patent_doc_number] => 20200399352
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-24
[patent_title] => METHODS OF TREATING ALZHEIMER'S DISEASE
[patent_app_type] => utility
[patent_app_number] => 16/782654
[patent_app_country] => US
[patent_app_date] => 2020-02-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28806
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16782654
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/782654 | METHODS OF TREATING ALZHEIMER'S DISEASE | Feb 4, 2020 | Abandoned |
Array
(
[id] => 15960549
[patent_doc_number] => 20200164026
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-28
[patent_title] => Intranasal Delivery of Cell Permeant Therapeutics
[patent_app_type] => utility
[patent_app_number] => 16/738542
[patent_app_country] => US
[patent_app_date] => 2020-01-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15602
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16738542
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/738542 | Intranasal Delivery of Cell Permeant Therapeutics | Jan 8, 2020 | Abandoned |
Array
(
[id] => 16312396
[patent_doc_number] => 20200291134
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-17
[patent_title] => METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF CONFORMATION-SPECIFIC ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 16/712525
[patent_app_country] => US
[patent_app_date] => 2019-12-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13208
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16712525
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/712525 | METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF CONFORMATION-SPECIFIC ANTIBODIES | Dec 11, 2019 | Abandoned |
Array
(
[id] => 15963213
[patent_doc_number] => 20200165358
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-28
[patent_title] => METHODS AND COMPOSITIONS FOR EVALUATION AND TREATMENT OF SYNUCLEINOPATHIES
[patent_app_type] => utility
[patent_app_number] => 16/692382
[patent_app_country] => US
[patent_app_date] => 2019-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8272
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16692382
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/692382 | METHODS AND COMPOSITIONS FOR EVALUATION AND TREATMENT OF SYNUCLEINOPATHIES | Nov 21, 2019 | Abandoned |
Array
(
[id] => 15831949
[patent_doc_number] => 20200131256
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-30
[patent_title] => ANTI-PACAP ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 16/692236
[patent_app_country] => US
[patent_app_date] => 2019-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7995
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 57
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16692236
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/692236 | Anti-PACAP antibody | Nov 21, 2019 | Issued |
Array
(
[id] => 17330227
[patent_doc_number] => 11220680
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-01-11
[patent_title] => Polypeptide for treating pathological blood clots
[patent_app_type] => utility
[patent_app_number] => 16/691578
[patent_app_country] => US
[patent_app_date] => 2019-11-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 33
[patent_no_of_words] => 13346
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16691578
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/691578 | Polypeptide for treating pathological blood clots | Nov 20, 2019 | Issued |
Array
(
[id] => 15553951
[patent_doc_number] => 20200061387
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-27
[patent_title] => OPTOGENETIC THERAPEUTIC AND METHOD OF TREATING RETINAL DEGENERATIVE AND NEURODEGENERATIVE DISEASES
[patent_app_type] => utility
[patent_app_number] => 16/672899
[patent_app_country] => US
[patent_app_date] => 2019-11-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 1420
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16672899
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/672899 | OPTOGENETIC THERAPEUTIC AND METHOD OF TREATING RETINAL DEGENERATIVE AND NEURODEGENERATIVE DISEASES | Nov 3, 2019 | Abandoned |
Array
(
[id] => 16605975
[patent_doc_number] => 10906967
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-02-02
[patent_title] => Anti-transthyretin antibodies
[patent_app_type] => utility
[patent_app_number] => 16/669375
[patent_app_country] => US
[patent_app_date] => 2019-10-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 58
[patent_no_of_words] => 29317
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 93
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16669375
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/669375 | Anti-transthyretin antibodies | Oct 29, 2019 | Issued |
Array
(
[id] => 18468857
[patent_doc_number] => 20230203140
[patent_country] => US
[patent_kind] => A9
[patent_issue_date] => 2023-06-29
[patent_title] => HUMANISED ANTI-N-TRUNCATED AMYLOID BETA MONOCLONAL ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 17/282592
[patent_app_country] => US
[patent_app_date] => 2019-10-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17533
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17282592
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/282592 | HUMANISED ANTI-N-TRUNCATED AMYLOID BETA MONOCLONAL ANTIBODY | Oct 1, 2019 | Pending |
Array
(
[id] => 18468857
[patent_doc_number] => 20230203140
[patent_country] => US
[patent_kind] => A9
[patent_issue_date] => 2023-06-29
[patent_title] => HUMANISED ANTI-N-TRUNCATED AMYLOID BETA MONOCLONAL ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 17/282592
[patent_app_country] => US
[patent_app_date] => 2019-10-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17533
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17282592
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/282592 | HUMANISED ANTI-N-TRUNCATED AMYLOID BETA MONOCLONAL ANTIBODY | Oct 1, 2019 | Pending |
Array
(
[id] => 16284756
[patent_doc_number] => 20200278358
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-03
[patent_title] => METHOD OF DISTINGUISHING BETWEEN DIFFERENT NEURODEGENERATIVE DISEASES
[patent_app_type] => utility
[patent_app_number] => 16/588481
[patent_app_country] => US
[patent_app_date] => 2019-09-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20901
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16588481
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/588481 | METHOD OF DISTINGUISHING BETWEEN DIFFERENT NEURODEGENERATIVE DISEASES | Sep 29, 2019 | Pending |
Array
(
[id] => 15649713
[patent_doc_number] => 20200087386
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-19
[patent_title] => ANTI-TRANSTHYRETIN ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 16/584634
[patent_app_country] => US
[patent_app_date] => 2019-09-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37683
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -35
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16584634
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/584634 | Anti-transthyretin antibodies | Sep 25, 2019 | Issued |
Array
(
[id] => 15681287
[patent_doc_number] => 20200095307
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-26
[patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROMYELITIS OPTICA
[patent_app_type] => utility
[patent_app_number] => 16/577703
[patent_app_country] => US
[patent_app_date] => 2019-09-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37873
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16577703
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/577703 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROMYELITIS OPTICA | Sep 19, 2019 | Pending |